Reaktionsgleichung
C(OC([N:6]1[CH2:11][CH2:10][CH:9]([N:12]2[C:21](=[O:22])[C:20]3[C:15](=[CH:16][CH:17]=[C:18]([N+:23]([O-:25])=[O:24])[CH:19]=3)[N:14]([CH2:26][CH3:27])[C:13]2=[O:28])[CH2:8][CH2:7]1)=O)C.Br.C(N1C2C(=CC([N+]([O-])=O)=CC=2)C(=O)N(C2CCNCC2)C1=O)C.[Cl:53][C:54]1[N:63]=[C:62](Cl)[C:61]2[C:56](=[CH:57][C:58]([O:67][CH3:68])=[C:59]([O:65][CH3:66])[CH:60]=2)[N:55]=1>>[Cl:53][C:54]1[N:63]=[C:62]([N:6]2[CH2:11][CH2:10][CH:9]([N:12]3[C:21](=[O:22])[C:20]4[C:15](=[CH:16][CH:17]=[C:18]([N+:23]([O-:25])=[O:24])[CH:19]=4)[N:14]([CH2:26][CH3:27])[C:13]3=[O:28])[CH2:8][CH2:7]2)[C:61]2[C:56](=[CH:57][C:58]([O:67][CH3:68])=[C:59]([O:65][CH3:66])[CH:60]=2)[N:55]=1Komponenten
4
Edukt 3
Produkt 1
Versuchsvorschrift
The procedure similar to that described in Example 15 was repeated, except that 3.62 g (9.4 mmol) of 3-(1-ethoxycarbonyl-4-piperidinyl)-1-ethyl-1,2,3,4-tetrahydro-6-nitro-2,4-dioxoquinazoline (Compound ii) was used in place of Compound a, whereby 3.20 g of crude 1-ethyl -1,2,3,4-tetrahydro-6-nitro-2,4-dioxo-3-(4-piperidinyl)quinazoline hydrobromide (Compound jj) was obtained. The product (198.0 mg) was treated in the similar manner as in Example 40, except for the use of 2,4-dichloro-6,7-dimethoxy-quinazoline in place of 4-chloro-6,7-dimethoxy-quinazoline, to give 220.7 mg (yield: 78%) of Compound 79 as pale yellow crystals.
Aufarbeitung
- customwas obtained
Quellen und Nachweise
- ORD-Eintrag
- ord-36a9fd8353b0419e94fc11d1b35d6e04
- Quelldatensatz
- uspto-grants-1997_04
- Patentnummer
- US05624926
Verknüpfte Notizen
Wird geladen…